Neoadjuvant Chemo Boosts Structure Preservation Rates in Nasal, Sinus Cancer
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Sept. 18, 2024 -- Neoadjuvant platinum-based chemotherapy improves structure preservation (SP) for patients with T3, T4a, and selected T4b resectable nasal and paranasal sinus squamous cell carcinoma (NPNSCC) requiring orbital or skull base resection, according to a study presented at the annual meeting of the European Society for Medical Oncology, held from Sept. 13 to 17 in Barcelona, Spain.
Nabil F. Saba, M.D., from Winship Cancer Institute of Emory University in Atlanta, and colleagues reported the SP analysis in a study involving patients with T3, T4a, and selected T4b resectable NPNSCC. Participants were randomly allocated to receive surgery followed by postoperative radiation therapy of 60 Gy (standard arm) or the same treatment preceded by three cycles of neoadjuvant docetaxel 75 mg/m2 and cisplatin 75 mg/m2 (experimental arm). The SP rate and overall survival were the co-primary objectives.
After enrolling 29 patients, the study was closed due to slow accrual in November 2023. The researchers found that the overall SP rate was 32 percent among 22 evaluable patients, with rates of 15 and 56 percent in the standard arm and experimental arm, respectively. The overall orbit preservation rate was 55 percent, with rates of 46 and 67 percent in the standard and experimental arms, respectively. The overall skull base preservation rate was 55 percent, with rates of 38 and 78 percent, respectively, in the standard and experimental arms.
"Despite being unable to complete the planned accrual and reach a definitive answer, the study results are striking and support the use of neoadjuvant chemotherapy as an intervention that could improve the chance of organ preservation for these patients," Saba said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
ENDO: 1999 to 2020 Saw Significant Uptick in Obesity-Related Cancer Deaths
MONDAY, July 14, 2025 -- From 1999 to 2020, obesity-related cancer mortality increased significantly, according to a study presented at ENDO 2025, the annual meeting of the...
Management of Chronic Rhinosinusitis May Be Improving
MONDAY, July 14, 2025 -- During the past five years, there has been a marked reduction in chronic rhinosinusitis (CRS) severity, according to a study published online June 17...
Immune Checkpoint Inhibitor Affordability Tied to Widening Survival Disparity
FRIDAY, July 11, 2025 -- The introduction of immune checkpoint inhibitors (ICIs) was associated with a widening survival disparity between those with private insurance and those...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.